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ABSTRACT
This study aimed to investigate the association between human leukocyte antigen-B 
(HLA-B) alleles and nevirapine allergy in HIV patients in Indonesia. A case control study 
was conducted involving 147 HIV patients comprising of 50 patients with and 97 
patients without nevirapine allergy as control. The HLA-B allele typing was conducted by 
using polymerase chain reaction-sequence specific oligonucleotide probes (PCR-SSOP), 
followed by sequencing. Bivariate analysis using Chi-square (X2) test and multivariate 
logistic regression with significance level at p<0.05 were applied to analysis the data. 
Among 147 subjects, 34 with HLA-B alleles were identified. Bivariable analysis showed 
that HLA-B*58 allele was the most significant risk factor for the nevirapine allergy (OR 
= 3.67; 95% CI: 1.79 to 7.54), while HLA-B*35 allele was a protective factor (OR = 
0.18; 95% CI: 0.08 to 0.42). Multivariate logistic regression analysis showed that young 
men and HLA-B*58 allele were the significant risk factors of nevirapine allergy (OR: 4.63; 
95% CI: 2.02 to 10.61), while older women with the HLA-B*35 was able to reduce 
the risk of nevirapine allergy approximately 81% (OR: 0.19; 95% CI: 0.08 to 0.49). In 
conclusion, young male with the HLA-B*58 allele are the high risk factor for nevirapine 
allergy in Indonesian HIV patients.
ABSTRAK
Penelitian ini bertujun untuk mengkaji hubungan antara alel human leukocyte antigen-B 
(HLA-B) dengan kejadian alergi karena nevirapine pada pasien HIV Indonesia. Penelitian 
dengan rancangan kasus kontrol melibatkan 147 pasien HIV terdiri dari 50 pasien dengan 
alergi niverapin dan 97 pasien tidak alergi sebagai kontrol. Tipe alel HLA-B dilakukan 
dengan metode polymerase chain reaction-sequence specific oligonucleotide probes 
(PCR-SSOP) dilanjutkan dengan skuensing. Analisis bivariate dengan uji Chi-square 
(X2) dan regresi logistik multivariat dengan tingkat signifikan p <0.05 digunakan untuk 
menganalisis data. Diantara 147 subjek, 34 subjek teridentifikasi membawa alel HLA-B. 
Hasil analisis bivariat menunjukkan bahwa HLA-B *58 merupakan factor risiko nyata 
terjadinya alergi nevirapin (OR = 3,67; 95% CI: 1,79 to 7,54), sedangkan alel HLA-B *35 
merupakan faktor protektif (OR = 0,18; 95% CI: 0,08 to 0,42). Analisis regresi logistik 
multivariat menunjukkan lelaki muda dan alel HLA-B *58 faktor risiko nyata terjadinya 
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alergi nevirapin (OR: 4,63; 95% CI: 2,02 to 10,61), sedangkan wanita usia lanjut dengan 
HLA-B *35 dapat menurunkan risiko alergi niveripin sekitar 81% (OR: 0,19; 95% CI: 
0,08-0,49). Dapat disimpulkan, lelaki muda dengan alel HLA-B *58 mempunyai risiko 
tinggi menderita alergi nevirapine pada pasien HIV Indonesia.  
Key words: HIV – nevirapine – allergy – immunogenetics -  HLA-B*58
INTRODUCTION
The incidence of adverse drug reactions in 
patients with human immunodeficiency virus 
(HIV) infection has been widely reported. 
Allergic drug reactions in HIV patients is 100 
times higher than the general population and 
3-20% of them are caused by antiretroviral 
(ARV) drugs.1 Among antiretroviral which 
most commonly cause allergic reactions are 
nevirapine (NVP), delavirdine, efavirenz, 
abacavir and amprenavir.2 Nevirapine, a non-
nucleoside reverse transcriptase inhibitor 
(NNRTI) with high efficacy, is the first-line 
drugs and the drug of choice for pregnant 
women due to it effectively prevents infection 
of the fetus. It has been used extensively in 
countries with limited resources because of 
the relatively cheap price. However, NVP can 
cause hypersensitivity reactions, including 
liver toxicity in about 4.9% of cases3, systemic 
reactions and skin reactions in as many as 32-
48% cases4,5or severe adverse effects on the 
skin as Stevens-Johnson Syndrome (SJS) 
or toxic epidermal necrolysis (TEN) which 
estimated to occur in 0.3% cases.6 
Nevirapine with the trade name Neviral® 
began to be used in Indonesia as a part of 
combination therapy for HIV infection 
since 2004. Data of NVP allergy among 
human immunodeficiency virus infection/
acquired immune deficiency syndrome (HIV/
AIDS) patients in Indonesia has never been 
reported yet. A retrospective study conducted 
by Pudjiati in 2011 showed that of 182 
cases of HIV/AIDS treated patients in Dr. 
Sardjito General Hospital Yogyakarta, 11% 
experienced exanthema and more than 90% 
of them received NVP treatment.7
Differences in HLA type in HIV infected 
patients have been implicated in the variation 
of therapeutic response and toxicities of 
the ARV drugs. The hypothesis that ethnic 
differences play an important role in patient 
response to ARV drugs is supported by 
reports suggesting that patients from different 
ethnic groups showed different clinical and 
pharmacokinetics response of ARV drugs 
significantly.8 Previous studies concerning 
the role of genetic factors in the occurrence 
of NVP allergy was very limited and the 
results widely varied. Some studies indicated 
an association  between HLA class I and class 
II  and the development of exanthema due 
to NVP in different populations.9-12 A study 
in French reported a significant association 
between the HLA-DRB1*01 with the 
development of the exanthema patients treated 
with 2 NNRTI, while the HLA-DRB*0101 
associated with liver-associated side-effects 
of the NVP.13 In Australia, HLA-DRB1*0101 
was associated with allergic reactions of 
NVP.9 The HLA-Cw8 and HLA-B14 alleles 
in Sardinia, Italy,10 the HLA-Cw*08 allele in 
Japan,11  the HLA-Cw*04 and HLA-B*3505 
alleles in Thailand,14  the HLA-B35 allele in 
India,15 the HLA-Cw*04 allele in China,16 
were associated with side effects of NVP. 
A toxicogenomics of nevirapine-associated 
adverse events among populations reported 
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that cutaneous adverse events were associated 
HLA-Cw*04 and HLA-B*35 alleles among 
Asian population, HLA-Cw*04 allele among 
Africans population and  HLA-DRB*01 allele 
among European population.17
The high frequency of HLA-B among 
Indonesian populations has been reported in 
the previous study.18 This study was performed 
to investigate the neveripine-induced allergies 
in association with HLA-B alleles among 
Indonesian HIV patients.    
MATERIALS AND METHODS
Subjects
The study was designed by using a case-
control study involving 152 HIV patients 
who registered at the HIV/AIDS Clinic of 
Dr. Sardjito General Hospital, Panti Rapih 
Hospital, Bethesda Hospital, Panembahan 
Senopati Hospital, Yogyakarta, Indonesia. 
Patients who had experienced NVP allergy 
clinically manifested on the skin and/or 
abnormalities in AST and/or ALT were 
allocated into Case group; whereas patients 
who had consumed ARV within 6 months of 
therapy but tolerance or did not suffer from 
NVP allergy were allocated into Control 
group. The protocol of this study has been 
approved by the Health Research Ethics 
Committee of the Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta. 
HLA-B typing
Ten millimeter of peripheral blood sample 
were taken by venipuncture from all subjects 
both from the Case and the Control groups. The peripheral blood mononuclear cell 
(PBMC) were separated and  the DNA was 
isolated. Typing of HLA alleles was according 
to Itoh et al.19 using PCR-SSOP-Lumnex 
method, followed by sequencing. 
Statistical analysis
Data were analyzed using bivariate 
analysis with Chi-square (X2) test and 
using  multivariate logistic regression with 
significance level at p<0.05. Association 
between HLA and other risk factors with NVP 
allergy was expressed using Odds Ratio (OR) 
and 95 % confident intervals. 
RESULTS
Characteristic of subjects
A number of 152 subjects of HIV patient 
were included in this study, of whom 52 
subjects suffering NVP allergy and 100 tolerant 
subjects with no NVP allergy. TABLE 1 shows 
the different characteristic of the Case and the 
Control groups. Higher proportion of male 
were found in NVP allergy group compared 
to no NVP allergy group (OR= 2.17; CI: 
1.22 to 3.88). The median age was younger 
in the Case group compared to those in the 
control group (p<0.05). No different in  CD4 
cell count before ARV therapy, the median of 
body mass index (BMI) as well as the initial 
dose NVP were found between cases and 
controls. Maculopapular eruptions or allergic 
reaction grade 2nd (according to DAIDS) was 
the majority clinical manifestation (71.15%), 
while SJS were found in 7.69% of subjects. 
Hepatotoxicity was found in 31 subjects 
(59.62%) as shown in the elevation of the 
enzymes; 30.77% in the first degree, 15.38% 
in second degree, while 13.46% in 3rd and 4th 
degrees.
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TABLE 1. Characteristics of subjects in the Case and the Control groups.
Characteristics
Case 
(n = 52)
Control 
(n = 100)
Total 
(n=152)
p 
Gender [n (%)]
• Male 40 (76.92) 54 (54.00) 94 (61.84)
0.01
• Female 12 (23.10) 46 (46.00) 58 (38.16)
Age [n (%)]
• < 33 years old 32 (61.54) 39 (39.00) 71 (46.71)
0.01
• ≥ 33 years old 20 (38.46) 61 (61.00) 81 (53.29)
CD4 count before NVP
• ≥ 250 cells/mm3 14 (26.92) 19 (19.00) 33 (21.71)
0.26
• < 250 cells/mm3 38 (38.46) 81 (81.00) 119 978.29)
BMI base line
• < 18 21 (40.38) 44 (44.00) 65 (42.76)
0.67
• ≥ 18 31 (59.62) 56 (56.00) 87 (57.24)
Initial dose of NVP
• 2 x 200 mg/day 9 (17.31) 8 (8.00) 17 (11.18)
0.08
• 1 x 200 mg/day 43 (82.69) 92 (92.00) 135 (88.82)
HLA-B alleles 
Of the 52 subjects in the NVP allergy 
group and 100 samples of the control group, 
only 50 and 97 samples respectively could  be 
analyzed because the sequencing results on 5 
samples showed alkaline chain length of about 
150 bp which should be 482 bp in HLA-B 
gene. TABLE 2 shows 34 types of single 
allele of HLA-B as a result of a combination 
of bases 211-240. The results of the bivariate 
analysis of 34 types of HLA-B alleles, 17 
types of HLA-B alleles were significantly 
associated with NVP allergy (p <0.05) with the 
highest OR in HLA-B*58 (OR = 3.67; 95% 
CI: 1.78 to 7.53), while HLA-B*35 showed a 
protective allele for NVP allergy (OR = 0.18; 
93% CI: 0.08 to 0.42).
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TABLE 2. Association of HLA-B alleles and NVP allergy
Allele NVP allergy  
[n (%)]
Control
[n (%)]
p OR (95% CI)
B*07 21 (42.00) 20 (20.62) 0.01 2.79 (1.32-5.88)
B*08 21 (42.00) 18 (18.56) 0.00 3.18 (1.49-6.80)
B*13 17 (34.00) 13 (13.40) 0.00 3.33 (1.46-7.61)
B*14 4 (8.00) 7 (7.22) 1.00 1.12 (0.31-4.02)
B*15    31 (62.00) 35 (36.08) 0.00 2.89 (1.43-5.85)
B*18 23 (46.00) 30 (30.93) 0.07 1.90 (0.94-3.84)
B*27 15 (30.00) 24 (24.74) 0.49 1.30 (0.61-2.79)
B*35 9 (18.00) 53 (54.64) 0.00 0.18 (0.08-0.47)
B*37 28 (56.00) 36 (37.11) 0.03 2.16 (1.08-4.32)
B*38 21 (42.00) 19 (19.59) 0.00 2.19 (1.52-6.83)
B*39 23 (46.00) 20 (20.62) 0.00 3.28 (1.56-6.89)
B*40 32 (64.00) 35 (36.08) 0.00 3.15 (1.55-6.41)
B*41 1 (2.00) 4 (4.12) 0.85 0.47 (0.05-4.35)
B*42 5 (10.00) 6 (6.19) 0.67 1.69 (0.49-5.82)
B*44 33 (66.00) 35 (36.08) 0.00 3.44 (1.68-7.04)
B*45 1 (2.00) 5 (5.15) 0.63 0.38 (0.04-3.31)
B*46 32 (64.00) 38 (39.18) 0.00 2.76 (1.36-5.60)
B*47 1 (2.00) 4 (4.12) 0.85 0.47 (0.05-4.36)
B*48 5 (10.00) 6 (6.19) 0.62 1.69 (0.49-5.82)
B*49 22 (44.00) 23 (23.71) 0.02 2.53 (1.22-5.24)
B*51 33 (66.00) 43 (44.32) 0.01 2.44 (1.20-4.95)
B*52 32 (64.00) 37 (38.14) 0.00 2.88 (1.42-5.85)
B*53 20 (40.00) 24 (24.74) 0.06 2.03 (0.98-4.21)
B*55 15 (30.00) 19 (19.59) 0.16 1.76 (0.80-3.86)
B*56 31 (62.00) 32 (32.99) 0.00 3.31 (1.63-6.76)
B*57 16 (32.00) 28 (28.87) 0.69 1.16 (0.55-2.43)
B*58 28 (56.00) 25 (25.77) 0.00 3.67 (1.78-7.53)
B*59 4 (8.00) 6 (6.19) 0.95 1.32 (0.35-4.91)
B*67 4 (8.00) 6 (6.19) 0.95 1.32 (0.35-4.91)
B*73 4 (8.00) 6 (6.19) 0,95 1.32 (0.35-4.91)
B*78 17 (34.00) 13 (13.40) 0.00 3.33 (1.46-7.61)
B*81 4 (8.00) 6 (6.19) 0.95 1.32 (0.35-4.91)
B*82 4 (8.00) 6 (6.19) 0.95 1.32 (0.35-4.91)
B*83 4 (8.00) 6 (6.19) 0.95 1.32 (0.35-4.91)
Multivariate analysis of all variables 
(characteristic subjects and HLA types) was 
then performed to assess which variables 
which were most substantial as predictors for 
the NVP allergy in HIV patients. The 2-digit 
single HLA alleles that shown the highest risk 
for NVP allergy was HLA-B*58 (OR: 4.63; 
95% CI: 2.02 to 10.61), and that shown a high 
protection was HLA-B*35 (OR: 0.19; 95% 
CI: 0.08 to 0.49). Male and younger individual 
were risk factors for the occurrence of NVP 
allergies (TABLE 3).
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TABLE 3.  Multivariate analysis of subject characteristics and single allele HLA-B 
sequences 2 digits for NVP allergy
Variables OR (95% CI)
unadjusted
OR (95% CI)
adjusted
Gender 
Male
2.84 (1.33-6.04) 2.63 (1.23-5.63)
Female
Age
< 33 years old
2.84 (1.33-6.04) 2.63 (1.23-5.63)
≥ 33 years old
HLA-B*07 2.79 (1.32-5.88) 2.74 (1.19-6.32)
HLA-B*08 3.18 (1.49-6.80) 3.27 (1.39-7.71)
HLA-B*15 2.89 (1.43-5.85) 3.20 (1.47-6.96)
HLA-B*18 1.90 (0.94-3.84) 2.10 ( 0.96-4.58)
HLA-B*35 0.18 (0.08-0.42) 0.19 (0.08-0.49)
HLA-B*37 2.16 (1.08-4.32) 2.41 (1.11-5,23)
HLA-B*38 2.19 (1.52-6.83) 2.93 (1.26-6.84)
HLA-B*39 3.28 (1.56-6.89) 3.21 (1.40-7.35)
HLA-B*40 3.15 (1.55-6.41) 3.20 (1.47-6.96)
HLA-B*44 3.44(1.68-7.04) 3.79 (1.72-8.34)
HLA-B*46 2.76 (1.36-5.60) 2.98 (1.37-6.50)
HLA-B*49 2.53 (1.22-5.24) 2.36 (1.04-5.36)
HLA-B*51 2.44 (1.20-4.95) 2.96 (1.35-6.49)
HLA-B*52:                 2.88 (1.42-5.85) 3.58 (1.63-7.89)
HLA-B*56 3.35 (1.63-6.76) 3.57 (1.64-7.79)
HLA-B*58 3.67 (1.78-7.53) 4.63 (2.02-10.61)
HLA-B*78 3.33 (1.46-7.61) 4.00 (1.50-10.67)
DISCUSSION
This study found that men were more 
likely to have NVP allergy compared to 
women (78%: 22%). However, if severity 
of NVP allergy was taken into account 
women were more severe than men (18.18%: 
17.95%). This is in contrast to previous 
studies that NVP allergy was more common 
in faemale.15,20-24 According to Soldin et al.25 
there are differences in pharmacokinetics, 
drug effects and toxicities of drugs between 
men and women, in addition to many 
influential factors, such as socio-cultural 
differences, behavioral factors, body size, 
body composition, genetic, biochemical and 
hormonal factors. Another explanation that 
men had higher risk to women was the BMI 
(<18) in men seven times lower than women 
(9.2%: 1.3%); although in this study low BMI 
statistically was not a significant risk factor of 
NVP  allergy.
In this study, younger age, under 33 
years of age was at risk for the occurrence of 
NVP allergy. This is contrast with the study 
of Ananworanich et al.23 which showing no 
relationship between age and the incidence 
of NVP allergy.  Warrington and Silviu-Dan26 
suggested that the drug allergy commonly 
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occurred in young adults and the middle age. 
Jimmy and Padma27 demonstrated that the 
type of ADR type A was significantly more 
common in older adults (85.9%), while ADR 
type B were more common in adults (35%).
Sequencing in the family level (two digit 
sequences) in 147 subjects (50 cases and 97 
controls), identified 34 alleles of HLA-B. The 
highest frequency of allele in this population 
was HLA-B*51 (51.70%). This is consistent 
with the results reported by Yuliwulandari 
et al.18 in healthy subjects, that shown the 
highest frequency of HLA-B (40 alleles); 
and the mostly frequently of HLA-B*15.02 
(11.6%) and HLA-B*15.13 (11.2%). A study 
in Malaysian population found 15 types of 
allele HLA-A, 29-type allele HLA-B, and 14 
types of HLA-DR alleles; with the highest 
frequency of HLA-A*24 (35%), HLA-B*15 
(26%), and HLA-DRB1*15 (28%).28  
Bivariate analysis of 34 types of single 
allele HLA-B sequence of two digits, 
demonstrated that 17 types of alleles that B*07, 
B*08, B*13, B*15, B*35, B*37, B*38, B*39, 
B*40, B*44, B*46, B*49, B*51, B*52, B*56, 
B*58 and B*78 were significantly  associated 
with NVP allergy, with the highest risk was in 
HLA-B*58 alleles (OR = 3.67; 95% CI: 1.78 
to 7.53), while the allele HLA-B*35 alleles 
were significantly as  protection alleles (OR 
= 0.18; 95% CI: 0.08 to 0.42). This result was 
different to the previous studies in Sardinia 
Italy that HLA-B*14,10  and in Japan that 
HLA-B*3505,11 were the high risk factors of 
NVP allergy.12 Another studies in India and in 
China consistently found the HLA-B*35 was 
the risk factor of NVP allergy.15,16
HLA alleles responsible for the risk 
factors for NVP allergy in this study were 
different from previous studies. In addition 
to the ethnic differences, the other possible 
differences was due to the focus of the study 
in which we included allergic manifestation 
both the skin and the liver. The study of 
Likanonsakul et al.14 only observed on skin 
manifestations which they suggested that the 
degree of linkage disequilibrium between 
alleles HLA-B, HLA-C or other HLA alleles 
and individuals from other HLA loci and / or 
other genes occurs between ethnic groups. 
As demonstrated in several studies that 
allele HLA-Cw*04 was associated with the 
progression toward AIDS in the Caucasian 
but it showed a protective effect on African 
American.29 Another study conducted by 
Ananworanich et al.23 found that the exanthema 
due to NVP allergy 2.8 times more prevalent in 
Thais than in white skin population.  Study on 
Chinese and Thai populations showed that the 
SJS/TEN for carbamazepine were associated 
with HLA-B*1502, but not in Caucasian and 
Japanese populations as B*1502 allele is 
extremely rare in the Caucasian and Japanese 
population.30-33
The finding of various HLA-B alleles 
play role as risk factors in this study may 
also be due to the fact that these alleles were 
found in the Mongoloid race which comprised 
of Indonesian18, in Malaysian,28 and in north 
of Chinese.34 The finding of HLA-B*35 type 
allele as a protective factor for NVP allergy in 
this study gives an opportunity to further study 
to the role of CD
8
 T cells in type IV drug allergy, 
in contrasts to the studies in other countries 
showing the HLA-B*35 as a strong risk factor 
for nevirapine allergy (OR=18,34).17 Further 
studies are required to perform to confirm the 
role of these alleles in restriction to CD
8
+ cells 
related to NVP allergy.
CONCLUSION
This result shows that men, younger age 
and HLA-B*58 allele are the significant risk 
factors of NVP allergy (OR: 4.634; 95% CI: 
2.024 to 10.611), while women older age with 
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the HLA-B*35 is able to reduce the risk of 
NVP allergy (OR: 0.191; 95% CI: 0.075 to 
0.487).
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